alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro
/in Hepatocellular Carcinoma, International PublicationsA study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model
/in Colorectal Cancer, International PublicationsTargeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
/in Breast Cancer, Dendritic Cells, International PublicationsVaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
/in Breast Cancer, Dendritic Cells, International PublicationsHepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro
/in Chronic Virus Hepatitis, International PublicationsA novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model
/in Colorectal Cancer, International PublicationsSuccessful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice
/in Colorectal Cancer, International PublicationsA dendritic cell-based vaccine for treating HIV infection: background and preliminary results
/in HIV/AIDS, International PublicationsDendritic cell vaccine strategies for renal cell carcinoma
/in Hypernephroma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer